Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AgomAb Therapeutics NVAGMB · Entity 5259 | Director | September 11, 2026 | September 15, 2026 |
| CRISPR Therapeutics AGCRSP · Entity 3852 | Chief Medical Officer | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AgomAb Therapeutics NV
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.94 · Expires 2036-01-15 | Direct | 56,328 |
Reported balance
After 2026-09-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-11 · Grant · Acquired 56,328 · Balance 56,328 F1: The common shares may be represented by American Depositary Shares, each of which currently represents one common share. F2: The exercise price is reported in U.S. dollars and reflects the conversion from EUR to USD at an exchange rate of $1.1616 per EUR 1.00 as of September 10, 2026. F3: 33% of the shares underlying this option shall vest on September 11, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
F2: The exercise price is reported in U.S. dollars and reflects the conversion from EUR to USD at an exchange rate of $1.1616 per EUR 1.00 as of September 10, 2026.
F3: 33% of the shares underlying this option shall vest on September 11, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
CRISPR Therapeutics AG
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 22,000 |
Reported balance
After 2026-05-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 22,000 · Balance 22,000 F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2: This restricted stock unit award was granted on May 29, 2026 with respect to 22,000 Common Shares, with 100% of the shares vesting on November 29, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2: This restricted stock unit award was granted on May 29, 2026 with respect to 22,000 Common Shares, with 100% of the shares vesting on November 29, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 15, 2026 20:06 UTC | AgomAb Therapeutics NV AGMB · Entity 5259 | GrantStock Option (Right to Buy) · Derivative | 56,328 | $0.00 Strike: $13.94 | $0.00 |
DisclosureSEC source: 0001104659-26-107915 · tm2625420-3_4seq1.xml · derivative · entry 1 Patel Naimish · CIK 0002021679 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,328 Underlying: Common shares · 56,328 shares Expires 2036-01-15 F1 · derivative.exercise_price: The common shares may be represented by American Depositary Shares, each of which currently represents one common share. F2 · derivative.exercise_date: The exercise price is reported in U.S. dollars and reflects the conversion from EUR to USD at an exchange rate of $1.1616 per EUR 1.00 as of September 10, 2026. F3 · derivative.underlying: 33% of the shares underlying this option shall vest on September 11, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,786 | $55.62 | $210,577.32 |
DisclosureSEC source: 0001193125-26-251817 · ownership.xml · nonDerivative · entry 2 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,357 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 21:41 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-253926 · ownership.xml · derivative · entry 1 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Shares · 22,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: This restricted stock unit award was granted on May 29, 2026 with respect to 22,000 Common Shares, with 100% of the shares vesting on November 29, 2028. F2 · derivative.expiration_date: This restricted stock unit award was granted on May 29, 2026 with respect to 22,000 Common Shares, with 100% of the shares vesting on November 29, 2028. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-251817 · ownership.xml · derivative · entry 3 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on May 28, 2024 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on May 28, 2025, (ii) one quarter of the shares vesting on May 28, 2026, (iii) one quarter of the shares vesting on May 28, 2027, and (iv) one quarter of the shares vesting on May 28, 2028. F3 · derivative.expiration_date: This restricted stock unit award was granted on May 28, 2024 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on May 28, 2025, (ii) one quarter of the shares vesting on May 28, 2026, (iii) one quarter of the shares vesting on May 28, 2027, and (iv) one quarter of the shares vesting on May 28, 2028. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-251817 · ownership.xml · nonDerivative · entry 1 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 21:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-122267 · ownership.xml · derivative · entry 2 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F4 · derivative.exercise_date: This restricted stock unit award was granted on March 20, 2026 with respect to 30,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030. F4 · derivative.expiration_date: This restricted stock unit award was granted on March 20, 2026 with respect to 30,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 21:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 38,499 | $0.00 Strike: $46.24 | $0.00 |
DisclosureSEC source: 0001193125-26-122267 · ownership.xml · derivative · entry 1 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,499 Underlying: Common Shares · 38,499 shares Expires 2036-03-20 F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F2 · derivative.exercise_date: This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,150 | $48.26 | $152,019.00 |
DisclosureSEC source: 0001193125-26-111286 · ownership.xml · nonDerivative · entry 2 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,143 F4 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 8,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-111286 · ownership.xml · derivative · entry 3 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,375 Underlying: Common Shares · 8,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F5 · derivative.exercise_date: This restricted stock unit award was granted on March 14, 2025 with respect to 32,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029. F5 · derivative.expiration_date: This restricted stock unit award was granted on March 14, 2025 with respect to 32,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 8,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-111286 · ownership.xml · nonDerivative · entry 1 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · balance_after: Includes 592 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. Read SEC document |
| October 03, 2025 Filed Oct 3, 2025 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $67.74 | $0.00 |
DisclosureSEC source: 0001193125-25-230508 · ownership.xml · derivative · entry 1 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Shares · 16,500 shares Expires 2035-10-03 F1 · derivative.exercise_date: This option was granted on October 3, 2025 with respect to 16,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 3, 2025. Read SEC document |
| May 30, 2025 Filed Jun 4, 2025 01:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-081361 · ownership.xml · derivative · entry 1 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: This restricted stock unit award was granted on May 30, 2025 with respect to 25,000 Common Shares, with 100% of the shares vesting on May 30, 2028. F2 · derivative.expiration_date: This restricted stock unit award was granted on May 30, 2025 with respect to 25,000 Common Shares, with 100% of the shares vesting on May 30, 2028. Read SEC document |
| May 29, 2025 Filed May 30, 2025 21:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,932 | $35.94 | $141,316.08 |
DisclosureSEC source: 0000950170-25-079822 · ownership.xml · nonDerivative · entry 2 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,068 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 28, 2025 Filed May 30, 2025 21:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-079822 · ownership.xml · derivative · entry 3 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on May 28, 2024 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on May 28, 2025, (ii) one quarter of the shares vesting on May 28, 2026, (iii) one quarter of the shares vesting on May 28, 2027, and (iv) one quarter of the shares vesting on May 28, 2028. F3 · derivative.expiration_date: This restricted stock unit award was granted on May 28, 2024 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on May 28, 2025, (ii) one quarter of the shares vesting on May 28, 2026, (iii) one quarter of the shares vesting on May 28, 2027, and (iv) one quarter of the shares vesting on May 28, 2028. Read SEC document |
| May 28, 2025 Filed May 30, 2025 21:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-079822 · ownership.xml · nonDerivative · entry 1 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| April 03, 2025 Filed Jan 27, 2026 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Shares | 1,508 | $32.96 | $49,703.68 |
DisclosureSEC source: 0001193125-26-024955 · ownership.xml · nonDerivative · entry 1 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,508 F1 · kind: The purchase of Common Shares reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,508 shares, with a subsequent sale of Common Shares at a price of $35.94 per share on May 29, 2025 pursuant to a mandatory "sell to cover" provision in an award agreement covering a restricted stock unit that vested on such date (and which was reported on a separate Form 4 filing dated May 30, 2025). The Reporting Person has agreed to pay to the Issuer $4,493.84, representing the full amount of the profit realized in connection with the short-swing transaction. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-041470 · ownership.xml · derivative · entry 2 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Shares · 32,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 14, 2025 with respect to 32,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 14, 2025 with respect to 32,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 46,667 | $0.00 Strike: $42.12 | $0.00 |
DisclosureSEC source: 0000950170-25-041470 · ownership.xml · derivative · entry 1 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,667 Underlying: Common Shares · 46,667 shares Expires 2035-03-14 F1 · derivative.exercise_date: This option was granted on March 14, 2025 with respect to 46,667 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 14, 2025. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 18,333 | $0.00 Strike: $49.00 | $0.00 |
DisclosureSEC source: 0000950170-24-115697 · ownership.xml · derivative · entry 1 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,333 Underlying: Common Shares · 18,333 shares Expires 2034-10-16 F1 · derivative.exercise_date: This option was granted on October 16, 2024 with respect to 18,333 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 16, 2024. Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:15 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-065943 · ownership.xml · derivative · entry 2 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on May 28, 2024 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on May 28, 2025, (ii) one quarter of the shares vesting on May 28, 2026, (iii) one quarter of the shares vesting on May 28, 2027, and (iv) one quarter of the shares vesting on May 28, 2028. F3 · derivative.expiration_date: This restricted stock unit award was granted on May 28, 2024 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on May 28, 2025, (ii) one quarter of the shares vesting on May 28, 2026, (iii) one quarter of the shares vesting on May 28, 2027, and (iv) one quarter of the shares vesting on May 28, 2028. Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:15 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $54.84 | $0.00 |
DisclosureSEC source: 0000950170-24-065943 · ownership.xml · derivative · entry 1 Patel Naimish · CIK 0002021679 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Shares · 85,000 shares Expires 2034-05-28 F1 · derivative.exercise_date: This option was granted on May 28, 2024 with respect to 85,000 Common Shares. 25% of the shares shall vest on May 28, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.